Key Points
- Major shareholder Financial Lp Hrt bought 137,541 shares of NewGenIvf Group on May 22 at an average price of $0.99, spending about $136,166.
- The shareholder also bought another 27,993 shares on May 26 at $0.92 per share, adding to recent insider buying in NIVF.
- NewGenIvf Group’s stock was trading near $0.85, while analysts currently have a Sell consensus rating on the company.
NewGenIvf Group Limited (NASDAQ:NIVF - Get Free Report) major shareholder Financial Lp Hrt bought 27,993 shares of the firm's stock in a transaction dated Tuesday, May 26th. The shares were acquired at an average price of $0.92 per share, for a total transaction of $25,753.56. Following the completion of the transaction, the insider owned 139,878 shares in the company, valued at $128,687.76. This represents a 25.02% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Financial Lp Hrt also recently made the following trade(s):
- On Friday, May 22nd, Financial Lp Hrt bought 137,541 shares of NewGenIvf Group stock. The shares were acquired at an average price of $0.99 per share, for a total transaction of $136,165.59.
NewGenIvf Group Price Performance
Shares of NewGenIvf Group stock opened at $0.85 on Thursday. The company has a current ratio of 3.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.16. The firm's 50-day simple moving average is $1.68 and its 200-day simple moving average is $6.93. NewGenIvf Group Limited has a twelve month low of $0.72 and a twelve month high of $1,839.00.
NewGenIvf Group (NASDAQ:NIVF - Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported ($287.24) earnings per share for the quarter. The firm had revenue of $1.42 million for the quarter. Equities analysts forecast that NewGenIvf Group Limited will post 4.74 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a "sell (d)" rating on shares of NewGenIvf Group in a research report on Monday, April 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Sell".
Check Out Our Latest Report on NewGenIvf Group
About NewGenIvf Group
(
Get Free Report)
NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People's Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.
NewGenIVF's service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
